132 related articles for article (PubMed ID: 24908114)
1. Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer.
Kikuchi S; Kaibe N; Morimoto K; Fukui H; Niwa H; Maeyama Y; Takemura M; Matsumoto M; Nakamori S; Miwa H; Hirota S; Sasako M
Gastric Cancer; 2015 Jul; 18(3):485-94. PubMed ID: 24908114
[TBL] [Abstract][Full Text] [Related]
2. Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study.
Kanda T; Yajima K; Kosugi S; Ishikawa T; Ajioka Y; Hatakeyama K
Gastric Cancer; 2012 Jul; 15(3):235-44. PubMed ID: 22033890
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer.
Inokuchi M; Nakagawa M; Baogok N; Takagi Y; Tanioka T; Gokita K; Okuno K; Kojima K
Anticancer Res; 2018 Mar; 38(3):1685-1693. PubMed ID: 29491103
[TBL] [Abstract][Full Text] [Related]
4. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
5. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
7. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy.
Aoyama T; Yoshikawa T; Miyagi Y; Kameda Y; Shirai J; Hayashi T; Cho H; Oshima T; Yukawa N; Rino Y; Masuda M; Tsuburaya A
Surg Today; 2013 Dec; 43(12):1390-7. PubMed ID: 23512532
[TBL] [Abstract][Full Text] [Related]
8. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
9. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of
Hatori S; Sakamaki K; Yokohori T; Kimura Y; Hiroshima Y; Hashimoto I; Komori K; Watanabe H; Kano K; Fujikawa H; Aoyama T; Numata M; Yamada T; Tamagawa H; Yamamoto N; Ogata T; Shizawa M; Yukawa N; Morinaga S; Rino Y; Masuda M; Saeki H; Miyagi Y; Oshima T
Anticancer Res; 2021 Jul; 41(7):3583-3588. PubMed ID: 34230154
[TBL] [Abstract][Full Text] [Related]
11. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.
Okuyama T; Korenaga D; Edagawa A; Itoh S; Oki E; Kawanaka H; Ikeda Y; Kakeji Y; Tateishi M; Tsujitani S; Takenaka K; Maehara Y
Surg Today; 2012 Aug; 42(8):734-40. PubMed ID: 22278622
[TBL] [Abstract][Full Text] [Related]
13. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
14. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy.
Ema A; Yamashita K; Sakuramoto S; Wang G; Mieno H; Nemoto M; Shibata T; Katada N; Kikuchi S; Watanabe M
Gastric Cancer; 2014 Jan; 17(1):67-75. PubMed ID: 23801337
[TBL] [Abstract][Full Text] [Related]
15. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
16. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
Omura T; Shimada Y; Nagata T; Okumura T; Fukuoka J; Yamagishi F; Tajika S; Nakajima S; Kawabe A; Tsukada K
Oncol Rep; 2014 Feb; 31(2):613-8. PubMed ID: 24317477
[TBL] [Abstract][Full Text] [Related]
17. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Jun; 14(2):150-4. PubMed ID: 21327443
[TBL] [Abstract][Full Text] [Related]
18. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2013 Apr; 16(2):133-9. PubMed ID: 22527186
[TBL] [Abstract][Full Text] [Related]
20. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
